Physician profile
Dacy C Reimer
NPI 1144656851
$3,469.54
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,520 · 2022: $936 · 2023: $902 · 2024: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $599 · Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $598.50 |
| Food and Beverage | $415.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $2,870.50 | 2021-2024 | Rytary |
| Biogen, INC. | $140.64 | 2021-2023 | Vumerity, Tysabri |
| Biohaven Pharmaceuticals, INC. | $87.46 | 2021 | |
| Kyowa Kirin, INC. | $68.51 | 2021-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $64.29 | 2022-2023 | |
| Corium, LLC | $50.36 | 2023 | Adlarity |
| Abbott Laboratories | $47.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.41 | 2022 | |
| Ucb, INC. | $21.99 | 2022 | |
| Emd Serono, INC. | $20.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.05 | 2022 | |
| Pfizer INC. | $15.98 | 2023 | |
| Boston Scientific Corporation | $14.39 | 2022 | |
| Neurocrine Biosciences, INC. | $13.86 | 2021 | |
| Allergan, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dacy Reimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.